What is Chardan Capital’s Forecast for EYPT FY2026 Earnings?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Chardan Capital issued their FY2026 EPS estimates for EyePoint Pharmaceuticals in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($2.82) for the year. Chardan Capital has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

A number of other research analysts have also recently commented on the company. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $33.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Trading Down 1.6 %

Shares of EYPT stock opened at $6.24 on Wednesday. The company has a market cap of $428.87 million, a PE ratio of -3.12 and a beta of 1.41. The company’s fifty day simple moving average is $6.88 and its 200-day simple moving average is $8.28. EyePoint Pharmaceuticals has a 52 week low of $5.54 and a 52 week high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. increased its holdings in EyePoint Pharmaceuticals by 39.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company’s stock valued at $51,000 after buying an additional 1,940 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter worth approximately $59,000. Virtus ETF Advisers LLC bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at approximately $67,000. AlphaQuest LLC raised its position in shares of EyePoint Pharmaceuticals by 13,246.6% during the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after acquiring an additional 9,670 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in EyePoint Pharmaceuticals during the fourth quarter worth $76,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.